813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study

Abstract

Primary analysis of the phase 3 IMspire150 study (NCT02908672) demonstrated improved progression-free survival with first-line combination treatment with A+V+C vs P+V+C in patients (pts) with previously untreated BRAFV600 mutation–positive advanced melanoma. At the time of primary analysis (median follow-up 18.9 months), numerically lower rates of interval development of CNS mets were also seen with A+V+C vs P+V+C. Here we report updated exploratory analyses of incidence and time to development of CNS mets with A+V+C vs P+V+C with longer follow-up in the IMspire150 study.